ALNEV Stock Overview
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Neovacs S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.31 |
| 52 Week High | €32,000.00 |
| 52 Week Low | €0.29 |
| Beta | -868.81 |
| 1 Month Change | -55.73% |
| 3 Month Change | -84.51% |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALNEV | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -6.1% | 2.0% | 1.2% |
| 1Y | -100.0% | -8.2% | 4.0% |
Price Volatility
| ALNEV volatility | |
|---|---|
| ALNEV Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.3% |
| 10% least volatile stocks in FR Market | 2.3% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 23 | Hugo Brugiere | www.neovacs.com |
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies.
Neovacs S.A. Fundamentals Summary
| ALNEV fundamental statistics | |
|---|---|
| Market cap | €108.99k |
| Earnings (TTM) | -€5.00m |
| Revenue (TTM) | €53.48k |
2.0x
P/S Ratio0.0x
P/E RatioIs ALNEV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALNEV income statement (TTM) | |
|---|---|
| Revenue | €53.48k |
| Cost of Revenue | €3.63m |
| Gross Profit | -€3.58m |
| Other Expenses | €1.42m |
| Earnings | -€5.00m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.21 |
| Gross Margin | -6,686.05% |
| Net Profit Margin | -9,343.60% |
| Debt/Equity Ratio | 3.0% |
How did ALNEV perform over the long term?
See historical performance and comparison